Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama HM. et al, (2024), The Lancet. Infectious diseases
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.
Thiam LG. et al, (2024), NPJ vaccines, 9
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Harrison TE. et al, (2024), EMBO Mol Med
Plug and play virus-like particles for the generation of anti-toxin antibodies.
Edge RJ. et al, (2024), Toxicon: X, 23
Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection.
Dookie RS. et al, (2024), Infection and immunity
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.
Wang LT. et al, (2024), Cell
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW. et al, (2024), Cell reports. Medicine, 5
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Silk SE. et al, (2024), The Lancet Infectious Diseases
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
Barrett JR. et al, (2024), Frontiers in Immunology, 14
Respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination.
Mitsi E. et al, (2023), Nature communications, 14
Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults
Silk SE. et al, (2023), Med, 4, 668 - 686.e7
The dual action of human antibodies specific to Plasmodium falciparum PfRH5 and PfCyRPA: Blocking invasion and inactivating extracellular merozoites.
Weiss GE. et al, (2023), PLoS pathogens, 19
A systematic analysis of the human immune response to Plasmodium vivax
Bach FA. et al, (2023), Journal of Clinical Investigation
Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies.
Miura K. et al, (2023), Malaria journal, 22
Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine
Nielsen CM. et al, (2023), JCI Insight, 8
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793